ITERION THERAPEUTICS
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The companyโs lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada. It was founded in 2010 and is headquartered in Houston, Texas.
ITERION THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.iteriontherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
21.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Wordpress Plugins Nginx PHP Contact Form 7 PHP 7 GoDaddy SSL
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
SOV Therapeutics
SOV Therapeutics is a clinical stage biotechnology company developing oral testosterone replacement therapies for adult men.
Current Employees Featured
Founder
Investors List
GPG Ventures
GPG Ventures investment in Series B - Iterion Therapeutics
Sante Ventures
Sante Ventures investment in Series B - Iterion Therapeutics
Lumira Ventures
Lumira Ventures investment in Series B - Iterion Therapeutics
Viva BioInnovator
Viva BioInnovator investment in Series B - Iterion Therapeutics
GOOSE Capital
GOOSE Capital investment in Series B - Iterion Therapeutics
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Series B - Iterion Therapeutics
Sante Ventures
Sante Ventures investment in Series B - Iterion Therapeutics
AngelMD
AngelMD investment in Series B - Iterion Therapeutics
Sante Ventures
Sante Ventures investment in Series A - Iterion Therapeutics
Official Site Inspections
http://www.iteriontherapeutics.com
- Host name: 201.237.12.198.host.secureserver.net
- IP address: 198.12.237.201
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Iterion Therapeutics"
Our Science - Iterion Therapeutics
Tegavivint is a novel, small-molecule inhibitor that binds to TBL1 and disrupts the interaction between beta-catenin and TBL1.See details»
Our Team - Iterion Therapeutics
Iterion is guided by an experienced management team comprised of experts in early- and late-stage biopharmaceutical startups.See details»
Iterion Therapeutics - Craft
Iterion Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapeutics. It provides Tegavivint, a selective inhibitor of the Wnt/ฮฒ-catenin signaling โฆSee details»
Iterion Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Explore Iterion Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 4 news, and 20 literature, Disease Domain ...See details»
Iterion Therapeutics - LinkedIn
Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent โฆSee details»
Iteriontherapeutics / Iterion Therapeutics
. Check iteriontherapeutics valuation, traffic estimations and owner info. Full analysis about iteriontherapeutics.com.See details»
Iterion Therapeutics - VentureRadar
"Iterion Therapeutics is a clinical-stage company developing novel therapies for cancer and other diseases. The Companyโs lead product, Tegavivint, is a potent and selective inhibitor of โฆSee details»
Iterion Therapeutics 2025 Company Profile: Valuation, โฆ
Information on valuation, funding, cap tables, investors, and executives for Iterion Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Overview, News & Similar companies - ZoomInfo.com
Feb 20, 2024 View Iterion Therapeutics (www.iteriontherapeutics.com) location in Texas, United States , revenue, industry and description. Find related and similar companies as well as โฆSee details»
iteriontherapeutics.com Reviews: Is this site a scam or legit?
Is iteriontherapeutics.com a scam platform? Is it legit or risky? In this thorough analysis and review, we outline if the website is secure and trusted.See details»
Iterion Therapeutics: Employee Directory | ZoomInfo.com
Feb 13, 2024 Iterion Therapeutics Employee Directory Iterion Therapeutics corporate office is located in 2450 Holcombe Blvd Ste J608, Houston, Texas, 77021, United States and has 29 โฆSee details»
Iterion Therapeutics - LifeScienceHistory.com
Iterion Therapeutics, formerly Beta Cat, is a clinical stage biotechnology company developing novel targeted cancer therapeutics.See details»
Iterion Therapeutics: Revenue, Worth, Valuation & Competitors 2025
About Iterion Therapeutics Iterion Therapeutics is a Biotech related company founded in 2014 and based in Houston with 13 employees an estimated revenue of $1M, and. It has 10 competitors โฆSee details»
Iterion Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Iterion Therapeutics Inc. of Houston, TX. Get the latest business insights from Dun & Bradstreet.See details»
iTeos Therapeutics - Home - iTeos
ITeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients.See details»
Iterion Therapeutics - Crunchbase Company Profile & Funding
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics.See details»
Iterion Therapeutics - 2025 Company Profile - Tracxn
Jul 10, 2025 Iterion Therapeutics - Developer of therapeutics for the treatment of cancer. Raised a total funding of $31M over 12 rounds from 14 investors.See details»
Iterion Therapeutics Company Profile | Management and
Find contact information for Iterion Therapeutics. Learn about their Research & Development, Business Services market share, competitors, and Iterion Therapeutics's email format.See details»
Iterion Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Jul 14, 2021 Howard Liang joined gene writing company Tessera Therapeutics Inc. as president and CFO. Liang was most recently CFO and chief strategy officer at BeiGene Ltd. โฆSee details»
Working at Iterion Therapeutics | Glassdoor
See what employees say it's like to work at Iterion Therapeutics. Salaries, reviews, and more - all posted by employees working at Iterion Therapeutics.See details»